FDA approves new IOP-lowering glaucoma drug

Article

The FDA has approved Rescula (unoprostone isopropyl ophthalmic solution, Sucampo Pharmaceuticals Inc.) 0.15%, an sNDA for lowering IOP in patients with open-angle glaucoma or ocular hypertension.

Sucampo Pharmaceuticals Inc. announced it has received approval from the U.S. Food and Drug Administration (FDA) of an sNDA for Rescula (unoprostone isopropyl ophthalmic solution) 0.15% for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Sucampo intends to commercialize Rescula in the first quarter of 2013.

According to the approved product labeling, Rescula may be used as a first-line agent or concomitantly with other topical ophthalmic drug products to lower intraocular pressure.

Rescula is a BK (big potassium) channel activator, which is different from other IOP-lowering agents.

“Rescula provides IOP reduction by increasing trabecular flow, and may be an appropriate choice for eye specialists who are trying to balance efficacy with management of side effects,” said Ryuji Ueno, MD, PhD, chairman, chief executive officer, and chief scientific officer of Sucampo. “It has been shown to be an effective medicine in lowering IOP in patients with open-angle glaucoma and ocular hypertension while demonstrating an excellent systemic safety profile and an established ocular side effects profile.”

For more information, visit www.sucampo.com.

Recent Videos
Walline, OD, PhD, FAAO, outlines how to predict myopia progression and delay its onset in an exclusive interview with Optometry Times.
Jeffrey Walline, OD, PhD, FAAO, overviews a presentation he gave on the Bifocal Lenses in Nearsighted Kids 2 (BLINK2) cohort study at the Collaborative Community on Ophthalmic Innovation (CCOI).
Danica Marrelli, OD, FAAO, at Glaucoma 360 discussing visual field testing for patients with glaucoma
Walline, OD, PhD, FAAO, states that the best way to learn the benefits of artificial intelligence for your practice is to stay on top of continuing education attendance.
Jeffrey Walline, OD, PhD, FAAO, gives an overview of the AAO's 2024 and what to expect in 2025 and beyond.
Dr Jamie Kuzniar discusses higher order aberrations and premium scleral lenses
Abby Gillogly Harsch, OD, FAAO, FSLS, shares a specific complex case of scleral lens fitting that she presented on at this year's GSLS.
Sherrol Reynolds, OD, FAAO, values the ophthalmic-optometric collaboration on display at the summit, running from February 14-17, 2025 in San Juan, Puerto Rico.
© 2025 MJH Life Sciences

All rights reserved.